Komiya Toshiyuki, Miura Katsuyuki, Tsukamoto Jin, Okamura Mikio, Tamada Satoshi, Asai Toshihiro, Tashiro Koichiro, Kuwabara Nobuyuki, Iwao Hiroshi, Yoshikawa Junichi
Department of Nephrology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku Osaka 545-8585, Japan.
Int J Mol Med. 2004 Jan;13(1):133-8.
Oral adsorbent, AST-120 removes uremic toxins (such as indoxyl sulfate) and retards the progression of chronic renal failure (CRF). However, its mechanism of action has not been precisely clarified. Since indoxyl sulfate elicits renal tubular nuclear factor-kappaB (NF-kappaB) activation in vitro, the present experiments were conducted to elucidate the involvement of NF-kappaB in the beneficial effects of AST-120 using rats with 3/4 nephrectomy, a model of early-stage CRF. Daily administration of AST-120 was started at 6 weeks after 3/4 nephrectomy and continued for 18 weeks. Sham-operated rats, untreated CRF rats and AST-120-treated CRF rats were compared for NF-kappaB DNA-binding activity, gene expression and renal histology. Systolic blood pressure was increased in CRF rats, and this increase was not affected by AST-120. Blood urea nitrogen, serum creatinine and urinary protein were increased in CRF rats. Although AST-120 attenuated these increases, it did not do so to a statistically significant extent. Indoxyl sulfate, which was accumulated in serum of CRF rats, was significantly eliminated by AST-120. Renal cortical NF-kappaB DNA-binding activity was increased in CRF rats. AST-120 significantly inhibited this increase. Monocyte/macrophage infiltration and increased monocyte chemoattractant protein-1 (MCP-1) mRNA observed in CRF rats were attenuated by AST-120. Furthermore, AST-120 significantly blocked renal fibrosis with concomitant inhibition of transforming growth factor beta1 (TGF-beta1) gene expression. It appeared that AST-120 reduced NF-kappaB activation and possibly the activity of NF-kappaB-dependent pathways of interstitial inflammation including MCP-1 expression and macrophage infiltration. The anti-inflammatory effect of AST-120 mediated via inhibition of NF-kappaB is a possible mechanism by which AST-120 retards the progression of renal fibrosis in CRF.
口服吸附剂AST - 120可清除尿毒症毒素(如硫酸吲哚酚),并延缓慢性肾衰竭(CRF)的进展。然而,其作用机制尚未完全阐明。由于硫酸吲哚酚在体外可引起肾小管核因子-κB(NF-κB)激活,因此本实验使用3/4肾切除大鼠(一种早期CRF模型)来阐明NF-κB在AST - 120有益作用中的参与情况。在3/4肾切除术后6周开始每日给予AST - 120,并持续18周。对假手术大鼠、未治疗的CRF大鼠和AST - 120治疗的CRF大鼠进行NF-κB DNA结合活性、基因表达和肾脏组织学比较。CRF大鼠的收缩压升高,且这种升高不受AST - 120影响。CRF大鼠的血尿素氮、血清肌酐和尿蛋白增加。尽管AST - 120减轻了这些升高,但在统计学上没有显著意义。CRF大鼠血清中积累的硫酸吲哚酚被AST - 120显著清除。CRF大鼠肾皮质NF-κB DNA结合活性增加。AST - 120显著抑制了这种增加。AST - 120减轻了CRF大鼠中观察到的单核细胞/巨噬细胞浸润和单核细胞趋化蛋白-1(MCP - 1)mRNA增加。此外,AST - 120通过抑制转化生长因子β1(TGF-β1)基因表达,显著阻断了肾纤维化。似乎AST - 120降低了NF-κB激活,并可能降低了包括MCP - 1表达和巨噬细胞浸润在内的间质炎症的NF-κB依赖性途径的活性。AST - 120通过抑制NF-κB介导的抗炎作用是其延缓CRF肾纤维化进展的一种可能机制。